Thomas W. Flaig, MD, discusses the 2026 NCCN Guidelines updates for bladder cancer, highlighting the role of enfortumab vedotin, pembrolizumab, and the shift toward neoadjuvant ADC therapy.

Big men and bigger lineups have been standout factors for the teams that have reached the Final Four. Illinois is the ...

A new study from researchers at The University of Texas MD Anderson Cancer Center demonstrates that a specialized high-dose ...

Dr Thomas Flaig from the University of Colorado Anschutz discusses a paradigm shift in treating urothelial carcinoma patients ...

Bladder cancer does not always announce itself with dramatic pain or a sudden health crisis. In many people, the earliest bladder cancer symptoms look ordinary, brief, or easy to dismiss. A little ...

Non-Muscle Invasive Bladder Cancer Market · GlobeNewswire Inc. The non-muscle invasive bladder cancer (NMIBC) market size has ...

Key market opportunities include growing demand for advanced, targeted bladder therapies, increased R&D in personalized & ...

The 2026 NCCN Bladder Cancer Guidelines incorporate the IBCG five-factor model, introducing standardized risk stratification for intermediate-risk NMIBC. For decades, heterogeneity in ...

En bloc resection of bladder tumor has recently emerged as an alternative to TURBT aiming to improve surgical quality and pathological assessment.

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.

Partial cystectomy is a bladder-sparing surgical option associated with lower perioperative morbidity compared with RC. 8,34,35 Ideal candidates are highly selected and typically include patients with ...

“It’s just frustrating that you go to a GP and you have faith in them, but you don’t get taken seriously,” said Gemma Doherty SWNS Gemma Doherty experienced severe bleeding and pain for months before ...